Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Hyun Ah Yoon

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yoon_Hyuh_Ay_MD_420x504.jpg

First Name

Hyun Ah

Last Name

Yoon

NPI

1689962193

Faculty ID

15397

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

Selected Publications

<div id="cit_full" class="meta">
<p class="j">&nbsp;</p>
</div>
<div class="ab">&nbsp;</div>

EMR ID

56161

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Rodney L. Wright

https://assets.montefioreeinstein.org/profiles/images/Wright_Rodney_MD_2x.jpg

First Name

Rodney

Last Name

Wright

NPI

1639259195

Faculty ID

7019

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Areas of Expertise

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Wright&rsquo;s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women&rsquo;s health and maternal fetal medicine.

Research Focus

Following his clinical interests, Dr. Wright&rsquo;s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women&rsquo;s health.

Elsevier Profile

PubMed.gov URL

EMR ID

4235

Biography

<p>Rodney L. Wright, MD, MSc, is Director, Obstetrics and Gynecology, Wakefield Campus at Montefiore and Professor of Obstetrics and Gynecology and Women&rsquo;s Health, Division of Maternal Fetal Medicine at our Albert Einstein College of Medicine. Dr. Wright&rsquo;s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women&rsquo;s health and maternal fetal medicine.</p><p>After receiving his Bachelor of Arts in biology and psychology from Emory University, Dr. Wright went on to the University of Pennsylvania School of Medicine, earning his Doctor of Medicine. His post graduate training began at the University of California, Irvine, where he completed a four-year residency in obstetrics and gynecology. Several years later, Dr. Wright pursued a three-year fellowship in maternal fetal medicine at Montefiore-Einstein. After completing this, he continued his education at Einstein, earning his Master of Science in clinical research methods.</p><p>Following his clinical interests, Dr. Wright&rsquo;s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women&rsquo;s health. He&rsquo;s shared his research and expertise through many peer-reviewed journals, abstracts and invited presentations. He currently serves on the US Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission.</p><p>An active member within the community, Dr. Wright is a member of the New York State AIDS Advisory Council and the New York State Taskforce on Maternal Mortality. He was awarded the Bronx County Medical Society &ldquo;Peer to Peer&rdquo; Excellence in Medicine Award. Dr. Wright received the New York State Commissioner of Health Commissioner&rsquo;s Special Recognition Award in recognition of his work as co-chair of the New York State Perinatal HIV Guidelines Committee and service to the New York State Ending the Epidemic (AIDS) Task Force. Dr. Wright is board certified in both Maternal Fetal Medicine and Obstetrics and Gynecology and is a member of several professional organizations including the New York Obstetrical Society, the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists.</p>

Is Open Scheduling

Off

Allan W. Wolkoff

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wolkoff_Allan_W_MD_2574.jpg

First Name

Allan

Last Name

Wolkoff

NPI

1700961703

Faculty ID

3303

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span>Dr. Allan Wolkoff's interest in research was sparked when he worked in a biochemistry lab to help pay college bills. He began his medical studies at Dartmouth Medical College and transferred to the Albert Einstein College of Medicine where he obtained his M.D. degree. With the exception of a two year period when he was Clinical Associate in Gastroenterology-Hepatology in the Digestive Disease Branch, National Institute of Arthritis, Metabolism and Digestive Disease, he has remained at Albert Einstein. His early mentor, Irwin M. Arias, M.D. of the National Institutes of Health said of Wolkoff&rsquo;s work, &ldquo;He built an exemplary global reputation in hepatology research, education, training and scholarship. A major participant in the creation of the Marion Bessin Liver Research Center at Albert Einstein, Dr. Wolkoff has taken advantage of the strong, interactive basic science departments and is a leader in bridging understanding of hepatocyte biology with the pathogenesis of acquired and inheritable liver diseases.&rdquo; </span></p>
<p><span>Dr. Wolkoff is a pioneer in the combining of disciplines that inform basic understanding of hepatocyte function and relation to disease and is recognized worldwide for providing new windows into physiology and pathophysiology.&nbsp;</span><span>He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research. In addition, he has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented the AASLD Distinguished Service Award. In 2012, he received the&nbsp;<span>highly prestigious 2012 Distinguished Scientific Achievement Award from the American Liver Foundation.</span></span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diseases of the liver and biliary tract including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity, and unexplained jaundice.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Research interests include the mechanism by which the liver removes drugs and other compounds from the circulation and how its dysfunction may lead to drug toxicity.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

3553

Biography

<p>Allan W. Wolkoff, MD, is Chief, Hepatology, Herman Lopata Chair in Liver Disease Research and Professor, Medicine and Developmental &amp; Molecular Biology at Montefiore Einstein. His clinical focus centers on diseases of the liver and biliary tract, including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity and unexplained jaundice.</p><p>Dr. Wolkoff began his medical studies at Dartmouth Medical College and transferred to Einstein, where he earned his Doctor of Medicine in 1972. He completed an internship at Bronx Municipal Hospital Center in 1973 before becoming an Assistant Resident in Medicine until 1974. Following this, Dr. Wolkoff became a Clinical Associate in Gastroenterology-Hepatology at the National Institutes of Health (NIH) until 1976.</p><p>A pioneer in combining disciplines that inform basic understanding of hepatocyte function and relation to disease, Dr. Wolkoff is recognized worldwide for providing new windows into physiology and pathophysiology. His research interests include the mechanism by which the liver removes drugs and other compounds from circulation and how its dysfunction may lead to drug toxicity. He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research.</p><p>Dr. Wolkoff has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented with the American Association for the Study of Liver Diseases (AASLD) Distinguished Service Award. In 2012, he received the highly prestigious Distinguished Scientific Achievement Award from the American Liver Foundation. He was named Physician of the Year by the Greater New York Division of the American Liver Foundation in 2015 and won the National Leadership Award from the American Liver Foundation in 2022.</p>

Is Open Scheduling

Off

Gregory D. Weston

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/7b1b0bf0-f4ed-11ed-b165-5b052597da41.jpg

First Name

Gregory

Last Name

Weston

NPI

1003132861

Faculty ID

15038

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Weston&rsquo;s research interests include the epidemiology, mechanisms of resistance, and therapy of multi-drug resistant gram-negative infections, particularly Carbapenem-Resistant Enterobateriaceae.&nbsp; He works with mathematical modeling techniques to predict which patients are at high risk of CRE bloodstream infections.&nbsp; He also organizes Montefiore&rsquo;s participation in the CRACKLE II multicenter database of CRE infections.</p>
<p>Dr. Weston&rsquo;s inpatient clinical work is on a service dedicated to infectious disease consultation in the intensive care and step down units of Weiler hospital.&nbsp; This includes brief daily rounds with each unit to identify needs for consultation and provide antibiotic stewardship guidance.&nbsp; He is a member of the Montefiore Antibiotic Stewardship Team and also sees patients in an Outpatient Parenteral Antibiotic Therapy clinic.</p>
<p>Dr. Weston is a graduate of Regis High School in New York.&nbsp; He received his undergraduate education summa cum laude from the College of the Holy Cross in Worcester, Massachusetts.&nbsp; He received a medical&nbsp;degree from&nbsp;the College of Physicians and Surgeons of Columbia University in New York.&nbsp; He completed Internal&nbsp;Medicine residency at the Emory University School of Medicine in Atlanta, Georgia.&nbsp; Dr. Weston joined Montefiore Medical Center and the Albert Einstein College of Medicine in 2013 for his fellowship in Infectious Diseases.&nbsp; During Fellowship he completed a Master&rsquo;s of Science in Clinical Research degree in the Einstein Clinical Research Training Program.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28167547">Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.</a>&nbsp;Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN.&nbsp;&nbsp;<em>Antimicrobial Agents and Chemotherapy</em>&nbsp;2017; 61: e02349-16</p>
<p>A multicenter study measuring appropriateness of carbapenem use. Weston G, Jacob JT, Ray S, Varkey J, Gaynes RP.&nbsp;&nbsp;Infection Control and Hospital Epidemiology&nbsp;2013; 34: 1324-1326</p>

EMR ID

57217

Is Open Scheduling

Off

Louis M. Weiss

https://assets.montefioreeinstein.org/profiles/images/physphoto/Weiss_Louis_MD_420x504.jpg

First Name

Louis

Last Name

Weiss

NPI

1144310996

Faculty ID

4218

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><em><span style="text-decoration: underline;">Toxoplasma gondii</span></em>, microsporidiosis, stage differentiation, polar tube structure and function</p>
<p><strong>Toxoplasmosis:</strong> <em>Toxoplasma gondii</em> is a ubiquitous Apicomplexan protozoan parasite that infects humans, mammals and birds.&nbsp; Despite recent progress in understanding the biology of the rapidly replicating form (tachyzoite), very little is known about the cyst form (bradyzoite). The bradyzoite stage plays a critical role in maintenance of latent infection, the relapse of infections and the development of chronic neurologcial disease.&nbsp; Our research is focused on the identification of cyst wall&nbsp; (bradyzoite) proteins and how they function.&nbsp; &nbsp;</p>
<p><strong>Microsporidiosis:</strong> The phylum Microspora consists of organisms collectively known as microsporidia, that are "emerging" human and veterinary pathogens.&nbsp; A microsporidian-specific organelle, the polar tube, is involved in invasion. While the description of the polar tube as a unique microsporidian structure occurred over 100 years ago, the biochemical components of this structure and the mechanism of its formation during invasion remain to be definitively determined.&nbsp; The laboratory is focused on projects invovling the: (1) characterization of the structure and composition of the polar tube and spore wall, and (2) the identificiation of therapeutic targets for the treatment of microsporidiosis.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.

Research Focus

Investigates the biology of Toxoplasma gondii and its ability to cause latent infections, with a focus on the composition and structure of the T. gondii tissue cyst.

Elsevier Profile

Selected Publications

<p>Mayoral J, Guevara RB, Rivera-Cuevas Y, Tu V, Tomita T, Romano JD, Gunther-Cummins L, Sidoli S, Coppens I, Carruthers VB, Weiss LM.&nbsp; Dense Granule Protein GRA64 interacts with host cell ESCRT proteins during <em>Toxoplasma gondii</em> infection.mBio. 2022 Jun 22:e0144222. doi: 10.1128/mbio.01442-22.</p>
<p>Tomita T, Mukhopadhyay D, Han B, Yakubu R, Tu V, Mayoral J, Sugi T, Ma Y, Saeij JPJ, Weiss LM. <em>Toxoplasma gondii</em> matrix antigen 1 is a secreted immunomodulatory effector. mBio. 2021 May 18;12(3):e00603-21.&nbsp;</p>
<p>Flores J, Takvorian PM, Weiss LM, Cali A, Gao N. Human microsporidian pathogen <em>Encephalitozoon intestinalis</em> impinges on enterocyte membrane trafficking and signaling. J Cell Sci. 2021 Feb 15:jcs.253757. doi: 10.1242/jcs.253757.</p>
<p>Mayoral J, Tomita T, Tu V, Aguilan JT, Sidoli S, Weiss LM. <em>Toxoplasma gondii</em> PPM3C, a secreted protein phosphatase, affects parasitophorous vacuole effector export. PLoS Pathog. 2020 Dec 28;16(12):e1008771. doi: 10.1371/journal.ppat.1008771.&nbsp;</p>
<p>Mayoral J, Shamamian P Jr, Weiss LM. In Vitro Characterization of protein effector export in the bradyzoite stage of Toxoplasma gondii.&nbsp; mBio. 2020 Mar 10;11(2). pii: e00046-20. doi: 10.1128/mBio.00046-20. PMID: 32156805</p>
<p><span lang="EN">Tu V, Tomita T, Sugi T, Mayoral J, Han B, Yakubu RR, Williams T, Horta A, Ma Y, Weiss LM. The <em>Toxoplasma gondii</em> cyst wall interactome. mBio. 2020 Feb 4;11(1). pii: e02699-19. doi: 10.1128/mBio.02699-19.PMID: 32019789</span></p>
<p>Tu V, Mayoral J, Yakubu RR, Tomita T, Sugi T, Han B, Williams T, Ma Y, Weiss LM.MAG2, a <em>Toxoplasma gondii</em> bradyzoite stage-specific cyst matrix protein. mSphere. 2020 Feb 19;5(1). pii: e00100-20. doi:10.1128/mSphere.00100-20.PMID: 32075884</p>
<p><span lang="EN">Han B, Ma Y, Tu V, Tomita T, Mayoral J, Williams T, Horta A, Huang H, Weiss LM Microsporidia interact with host cell mitochondria via voltage-dependent anion channels using sporoplasm Surface Protein 1. mBio. 2019 Aug 20;10(4). pii: e01944-19. doi: 10.1128/mBio.01944-19. PMID: 31431557</span> <span lang="EN">PMC6703431</span></p>
<p><span lang="EN">Takvorian PM, Han B, Cali A, Rice WJ, Gunther L, Macaluso F, Weiss LM. An ultrastructural study of the extruded polar tube of<em> Anncaliia algerae</em> (Microsporidia). J Eukaryot Microbiol. 2019 Jul 22. doi: 10.1111/jeu.12751. PMID: 31332877</span></p>
<p><span lang="EN">Tomita T, Wang H, Wu P, Weiss LM.Stage-specific and selective delivery of caged azidosugars into the intracellular parasite <em>Toxoplasma gondii</em> by using an esterase-ester pair technique.&nbsp; mSphere. 2019 May 29;4(3). pii: e00142-19. doi: 10.1128/mSphere.00142-19. PMID: 31142619</span></p>
<p>Tu V, Mayoral J, Sugi T, Tomita T, Han B, Ma YF, Weiss LM. Enrichment and proteomic characterization of the cyst wall from in vitro <em>Toxoplasma gondii</em> cysts. mBio. 2019 Apr 30;10(2). pii: e00469-19. doi: 10.1128/mBio.00469-19. PMID: 31040239</p>
<p>Sugi T, Tu V, Ma Y, Tomita T, Weiss LM. <em>Toxoplasma gondii</em> requires glycogen phosphorylase for balancing amylopectin storage and for efficient production of brain cysts. mBio. 2017 Aug 29;8(4). pii: e01289-17. doi: 10.1128/mBio.01289-17.PMID: 28851850 PMC5574715</p>
<p>Yakubu RR, Silmon de Monerri NC, Nieves E, Kim K, Weiss LM. Comparative Monomethylarginine proteomics suggests that protein arginine methyltransferase 1 (PRMT1) is a significant contributor to arginine monomethylation in <em>Toxoplasma gondii</em>. Mol Cell Proteomics. 2017 Apr;16(4):567-580. doi: 10.1074/mcp.M117.066951. Epub 2017 Jan 31.PMID: 28143887</p>
<p>Han B, Polonais V, Sugi T, Yakubu R, Takvorian PM, Cali A, Maier K, Long M, Levy M, Tanowitz HB, Pan G, Delbac F, Zhou Z, Weiss LM. The role of microsporidian polar tube protein 4 (PTP4) in host cell infection. PLoS Pathog. 2017 Apr 20;13(4):e1006341. doi: 10.1371/journal.ppat.1006341. eCollection 2017 Apr. PMID: 28426751</p>
<p>Sugi T, Ma YF, Tomita T, Murakoshi F, Eaton MS, Yakubu R, Han B, Tu V, Kato K, Kawazu S, Gupta N, Suvorova ES, White MW, Kim K, Weiss LM. Toxoplasma gondii cyclic AMP-dependent protein kinase subunit 3 is involved in the switch from tachyzoite to bradyzoite development. mBio. 2016 May 31;7(3). pii: e00755-16. doi: 10.1128/mBio.00755-16. PMID: 27247232 PMCID: PMC4895117</p>
<p>El Bissati K, Suvorova ES, Xiao H, Lucas O, Upadhya R, Yan Fen Ma YF, Hogue Angeletti R, White MW, Weiss LM, Kim K <em>Toxoplasma gondii</em> arginine methyltransferase 1 (PRMT1) regulates centrosome dynamics during tachyzoite cell division. mBio. 2016 Feb 2;7(1):e02094-15. doi: 10.1128/mBio.02094-15. PMID: 26838719 PMCID: PMC4742710</p>
<p>Silmon de Monerri NC, Yakubu RR, Chen AL, Bradley PJ, Nieves E, Weiss LM, Kim K. The Ubiquitin proteome of <em>Toxoplasma gondi</em>i reveals roles for protein ubiquitination in cell-cycle transitions. Cell Host Microbe. 2015 Nov 11;18(5):621-33. doi: 10.1016/j.chom.2015.10.014. PMID: 26567513</p>
<p>Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM.The <em>Toxoplasma gondii</em> cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence.&nbsp; PLoS Pathog. 2013 Dec;9(12):e1003823. doi: 10.1371/journal.ppat.1003823. PMID:24385904</p>
<p>Morada M, Lee S, Gunther-Cummins L, Weiss LM, Widmer G, Tzipori S, Yarlett N. Continuous culture of <em>Cryptosporidium parvum</em> using hollow fiber technology. Int J Parasitol. 2015 Sep 2. pii: S0020-7519(15)00220-9. doi: 10.1016/j.ijpara.2015.07.006. PMID: 26341006</p>
<p>Ma Y, Weiss LM, Huang H. Inducible suicide vector systems for <em>Trypanosoma cruzi</em>. Microbes Infect. 2015 Jun;17(6):440-50. doi: 10.1016/j.micinf.2015.04.003. Epub 2015 Apr 18. PMID: 25899945</p>
<p>Nardelli SC, Che FY, Silmon de Monerri NC, Xiao H, Nieves E, Madrid-Aliste C, Angel SO, Sullivan WJ Jr, Angeletti RH, Kim K, Weiss LM.&nbsp; The Histone Code of <em>Toxoplasma gondii</em> Comprises Conserved and Unique Posttranslational Modifications. mBio. 2013 Dec 10;4(6). doi:pii: e00922-13. 10.1128/mBio.00922-13. PMID:24327343</p>
<p>Pombert JF,Selman M,Burki F,Bardell FT,Farinelli L,Solter LF,Whitman DW,Weiss LM, Corradi N, Keeling PJ.&nbsp;&nbsp; Gain and loss of multiple functionally related, horizontally transferred genes in the reduced genomes of two microsporidian parasites.&nbsp; Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12638-43. Epub 2012 Jul 16. PMID:22802648</p>
<p>Ghosh K, Nieves E, Keeling P, CaliA, Weiss LM. A new vesicular compartment in <em>Encephalitozoon cuniculi</em>. Microbes Infect. 2012 Apr;14(4):324-8. PMID:22166342</p>
<p>Ghosh K, Nieves E, Keeling P, Pombert JF, CaliA, Weiss LM. A branching network of proteinaceous filaments within the parasitophorous vacuole of<em> Encephalitozoon cuniculi</em> and <em>Encephalitozoon hellem</em>. Infect Immun. 2011 Jan 10.&nbsp;PMID: 21220485</p>
<p>Bouzahzah B, Nagajyothi F, Ghosh K, Takvorian PM, CaliA, Tanowitz HB, Weiss LM. Interactions of <em>Encephalitozoon cuniculi</em> polar tube proteins. Infect Immun. 2010 Jun;78(6):2745-53. Epub 2010 Mar 22. PMID: 20308291</p>
<p>Alvarado JJ, Nemkal A, Sauder JM, Russell M, Akiyoshi DE, Shi W, Almo SC, Weiss LM. Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470. Mol Biochem Parasitol. 2009 Aug 4. PMID: 19660503</p>
<p><strong>BOOKS</strong></p>
<p>Weiss LM and Kim K (eds.) <em>Toxoplasma gondii</em> the model Apicomplexan: Methods and Applications,&nbsp;&nbsp;Elsevier Press (Academic Press), 3rd edition, 2020.</p>
<p>Weiss LM and Reinke AW (eds.) Microsporidia: Current Advances in Biology, Springer, 2022.</p>
<p>Weiss LM and Becnel JJ (eds.) Microsporidia: Pathogens of Opportunity,&nbsp; Wiley-Blackwell, 2014.</p>

EMR ID

3600

Biography

<p>Louis M. Weiss, MD, MPH, is Vice Chair, Academic Affairs and Research, Pathology, Co-Director, Einstein Global Health Center and Professor, Pathology and Medicine (Infectious Diseases) at Montefiore Einstein. His clinical expertise is in the treatment and diagnosis of infectious diseases, with a focus on parasitology and global health.</p><p>After obtaining his Bachelor of Arts in biology and chemistry from Lehigh University in 1978, Dr. Weiss earned his Doctor of Medicine and Master of Public Health at Johns Hopkins University in 1982. Following this, Dr. Weiss completed his internship and residency in medicine at the University of Chicago in 1985 and an infectious diseases fellowship at Einstein Montefiore in 1989.</p><p>Dr. Weiss investigates the biology of <em>Toxoplasma gondii</em> and its ability to cause latent infections, with a focus on the composition and structure of the <em>T. gondii</em> tissue cyst. He also investigates the biology of infection due to the microsporidia, with a focus on the composition of the polar tube and how it functions during microsporidian invasion of a host cell. His research has been published in numerous peer-reviewed journals, articles, books and chapters, and he has presented this research both nationally and internationally. Dr. Weiss has been a reviewer for scientific journals including <em>mBIO</em>, the <em>Journal of Eukaryotic Microbiology</em>, the <em>American Journal of Tropical Medicine and Hygiene, PLOS Pathogens</em>, the <em>Journal of Infectious Diseases</em> and <em>Experimental Parasitology</em>, and is an editor for <em>mBIO</em> and <em>Microbes and Infection</em>.</p><p>Dr. Weiss is board certified in Internal Medicine and Infectious Diseases. He is a Fellow of the Infectious Diseases Society of America, the American College of Physicians and the American Academy of Microbiology of the American Society of Microbiology. In 2000, Dr. Weiss was inducted into the Leo M. Davidoff Society for his outstanding teaching of medical students.</p>

Is Open Scheduling

Off

Victoria Vapnyar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/dd685560-3db5-11ec-b813-25aca5adcea8.jpg

First Name

Victoria

Last Name

Vapnyar

NPI

1740556133

Faculty ID

17135

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

101619

Is Open Scheduling

Off

Clara Y. Tow

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tow_Clara_MD_420x504.jpg

First Name

Clara

Last Name

Tow

NPI

1174822845

Faculty ID

15844

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tow is a transplant hepatologist and Assistant Professor of Medicine at Montefiore Medical Center and Albert Einstein College of Medicine. She serves as the Clinical Site Director of Hepatology at the Weiler Division of MMC, Associate Program Director of the Gastroenterology &amp; Liver Diseases Fellowship Program, and the Co-Director of the AECOM Gastroenterology &amp; Hepatology Systems Course.</p>
<p>Dr. Tow holds a B.A. in Biological Sciences from Cornell University College of Arts and Sciences and graduated Phi Beta Kappa and Magna Cum Laude for her work in developmental research. While attending Weill Cornell Medical College, she developed her passion for transplant medicine and was awarded Alpha Omega Alpha and Honors in Research for her characterization of mitochondrial injury during ischemia-reperfusion injury. Dr. Tow completed her internship and residency in Internal Medicine at New York Presbyterian Hospital - Weill Cornell Medical Center, where she served as an education resident, and fellowship in Gastroenterology and Liver Diseases at Montefiore Medical Center. Subsequently she pursued her advanced fellowship training in Transplant Hepatology at New York Presbyterian Hospital &ndash; Columbia University Medical Center.</p>
<p>Dr. Tow has been at Montefiore/Einstein since 2018, where she specializes on the complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore family and that patient knowledge is power. Her goal is to provide patients and their families the best medical care that is embedded in kindness, dignity, and respect.&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer, and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity, and respect.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles, and abstracts.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

29458

Biography

<p>Clara Y. Tow, MD, is Clinical Site Director, Hepatology, Associate Program Director, Gastroenterology &amp; Liver Diseases Fellowship Program, Co-Course Director, Gastroenterology &amp; Hepatology Systems Course and Assistant Professor, Medicine at Montefiore Einstein. Dr. Tow specializes in the treatment of complications of advanced liver diseases, liver cancer and liver transplant. She believes every patient is an integral part of the Montefiore Einstein family and that patient knowledge is power. Her goal is to provide patients and their families with the best medical care embedded in kindness, dignity and respect.</p><p>After obtaining her Bachelor of Arts in biological sciences from Cornell University College of Arts and Sciences, Dr. Tow earned her Doctor of Medicine from Weill Cornell Medical College. She then completed her internship and residency in internal medicine at NewYork-Presbyterian Hospital, Weill Cornell Medical Center. Following this, she completed a gastroenterology and liver diseases fellowship at Montefiore Medical Center before pursuing her advanced fellowship training in transplant hepatology at NewYork-Presbyterian Hospital.</p><p>Dr. Tow&rsquo;s research focuses on social determinants of health and outcomes related to liver transplantation and the care of advanced liver disease. She has spoken at invited lectures nationally and internationally, and her work has been published in many peer-reviewed journals, books, chapters, review articles and abstracts.</p><p>Dr. Tow is board certified by the American Board of Internal Medicine in transplant hepatology, gastroenterology and internal medicine. She is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation (AST) and the European Association for the Study of the Liver (EASL). She is also a member of the Empire Liver Foundation and a Medical Advisor for the American Liver Foundation. In 2014, Dr. Tow won the Erica C. Jones &amp; Naina Sinha-Gregory Prize in Medicine.</p>

Is Open Scheduling

On

Kristine E. Torres-Lockhart

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0b28f080-c3c8-11eb-9ea2-7374238588d1.jpg

First Name

Kristine

Last Name

Torres-Lockhart

NPI

1023467115

Faculty ID

16568

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Kristine Torres-Lockhart, MD, FASAM is an Assistant Professor of Medicine in the Division of General Internal Medicine and Department of Psychiatry and Behavioral Sciences at Montefiore Medical Center and the Albert Einstein College of Medicine, as well as the founding director of the Addiction Consult Service at Montefiore's Weiler Hospital. She is Program Director of the Addiction Medicine Fellowship and Co-Director of the Addiction Medicine rotation for medical trainees. An addiction medicine and internal medicine physician, she leads the development and implementation of health system interventions to improve substance use disorder (SUD) care in acute care settings and transitions of care to post-acute and ambulatory care settings.</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><br />Dr. Torres-Lockhart provides SUD treatment, HIV/AIDS care, hepatitis C treatment, and general internal medicine care at several sites across Montefiore Medical Center, including a community health care center. She also actively teaches and supervises medical students, residents, and fellows. She is double board certified in addiction medicine and internal medicine and credentialed as an HIV specialist by the American Academy of HIV Medicine.&nbsp;<br /><br />Dr. Torres-Lockhart completed her fellowship training in addiction medicine at Montefiore Medical Center. Prior to arriving at Montefiore, she completed her residency training in internal medicine and primary care at Brigham and Women&rsquo;s Hospital in Boston, MA, where she also served as primary care chief medicine resident at the West Roxbury and Jamaica Plain Veterans Affairs Medical Centers. She received her undergraduate degree from Dartmouth College and her medical degree from the Geisel School of Medicine at Dartmouth. She is the PI for a HRSA training grant and co-PI for an OASAS training grant to lead the development of educational opportunities in building the addiction medicine workforce. She currently serves on the Board of Directors for the New York Society of Addiction Medicine previously as Communication Chair and now as Secretary.&nbsp;</p>

Research Areas

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Singh-Tan, S., <strong>Torres-Lockhart, K.</strong>, Jakubowski, A., Lu, T., Starrels, J., De Lima, P., Arnsten, J., Nahvi, S., Southern, W. (2023). Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder. &nbsp;/J Gen Intern Med/, 1-8. doi:10.1007/s11606-023-08202-7</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Jakukowski, A., Singh-Tan, S., <strong>Torres-Lockhart, K</strong>., Nahvi, S., Stein, M., Fox, A. D., &amp; Lu, T. (2023). Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. /Addict Sci Clin Pract, 18/(1), 31. doi:10.1186/s13722-023-00386-x</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Calcaterra, S. L., Bottner, R., Martin, M., Englander, H., Weinstein, Z. M., Weimer, M. B., Lambert, E., Ronan, M., Huerta, S., Zaman, T., Ullal, M., Peterkin, A., <strong>Torres-Lockhart, K.</strong>, Buresh, M., O&rsquo;Brien, M., Synder, H., Herzig, S. J. (2022). Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. /J Hosp Med, 17(9),/679-692/./doi:10.1002/jhm.12908</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong>Torres-Lockhart, K.</strong> E., Lu, T. Y., Weimer, M. B., Stein, M. R., &amp; Cunningham, C. O. (2022). Clinical Management of Opioid Withdrawal. /Addiction, 117/(9), 2540-2550. doi:10.1111/add.15818</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Cunningham, C. O., Khalid, L., Deng, Y., <strong>Torres-Lockhart, K.</strong>, Masyukova, M., Thomas, S., Zhang, C., Lu, T. (2022). A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. /J Subst Abuse Treat, 135/, 108641. doi:10.1016/j.jsat.2021.108641</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Joseph, G., <strong>Torres-Lockhart, K.</strong>, Stein, M. R., Mund, P. A., &amp; Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. /J Subst Abuse Treat, 122/, 108219. doi:10.1016/j.jsat.2020.108219</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">He, L., <strong>Torres-Lockhart, K.</strong>, Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S.M., Benes, C.H., Ellisen, L. W. (2013). Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. /Cancer Discov, 3/(3), 324-337. doi:10.1158/2159-8290.CD-12-0417</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., <strong>Torres-Lockhart, K</strong>., Prat, A., Anton, P., Cozar, P., Guzman, M., Grueso, J., Rodriguez, O., Calvo, M.T., Aura, C., Diez, O., Rubio, I.T., Perez, J., Rodon, J., Cortes, J., Ellisen, L.W., Scaltriti, M., Baselga, J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. /Cancer Discov, 2/(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348</p>

EMR ID

113089

Biography

<p>Kristine E. Torres-Lockhart, MD, FASAM, is Director, Addiction Medicine Fellowship Program at Montefiore Einstein, Founding Director, Addiction Consult Service at Weiler Hospital and Assistant Professor, General Internal Medicine and Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Torres-Lockhart is a general internist, primary care provider and addiction medicine specialist. She focuses on caring for people who use substances and people with substance use disorders, providing care in hospital settings and in outpatient clinics.</p><p>After obtaining her Bachelor of Arts in neuroscience from Dartmouth College in 2010, Dr. Torres-Lockhart earned her Doctor of Medicine at the Geisel School of Medicine at Dartmouth in 2016. She completed an internship and residency in internal medicine and primary care at Brigham and Women&rsquo;s Hospital in 2019. Following this, Dr. Torres-Lockhart completed a fellowship in addiction medicine at Montefiore Einstein in 2020.</p><p>Dr. Torres-Lockhart's research focuses on evidence-based and harm-reduction-oriented strategies for addressing substance use disorder care in acute care settings, integration of addiction medicine into medical education and optimizing transitions of care for people who use drugs. She has been principal investigator and co-investigator on funded research projects and her work has been published in numerous peer-reviewed publications. Dr. Torres-Lockhart has also shared her work through numerous invited presentations, abstracts and poster presentations. She is a reviewer for scientific journals, including Addiction Science and Clinical Practice, the Journal of Addiction Medicine, the Journal of Substance Abuse Treatment and the Journal of Hospital Medicine.</p><p>Dr. Torres-Lockhart is board certified by the American Board of Internal Medicine and the American Board of Preventive Medicine with certification in Addiction Medicine. She is a Fellow of the American Society of Addiction Medicine, board member of the New York Society of Addiction Medicine and member of the Association for Multidisciplinary Education and Research in Substance Use and Addiction. In 2022, Dr. Torres-Lockhart received the President&rsquo;s Award at the New York Society of Addiction Medicine&rsquo;s Annual Conference. In 2023, she received the Quality Improvement Champion honor at the United Hospital Fund's Tribute to Excellence in Health Care and was a Rising Star Nominee for the Department of Medicine&rsquo;s Physician Recognition Awards at Montefiore Einstein.</p>

Is Open Scheduling

Off